Residual Thromboembolic Risk and Outcomes of Oral Anticoagulation Discontinuation After Atrial Fibrillation Ablation: A Target Trial Emulation
Clicks: 5
ID: 323610
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
1.2
/100
5 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #22 of 79 articles by views in EP Europace
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND AND AIMS: Optimal management of oral anticoagulation (OAC) after atrial fibrillation (AF) ablation remains uncertain. We evaluated thromboembolic and bleeding outcomes associated with OAC discontinuation versus continuation at a clinically relevant 6-month post-ablation landmark. METHODS: This target trial emulation used data from a multicentre prospective registry in China. Patients with CHA2DS2-VA scores ≥2, no prior thromboembolism, and no atrial arrhythmia recurrence within 6 months after ablation were classified according to OAC discontinuation or continuation at the 6-month landmark. The primary outcome was the composite of stroke, systemic embolism, and major bleeding. Inverse probability weighting was applied, with intention-to-treat as the primary analysis. RESULTS: Among 8,339 patients (mean age 68 years; 40.5% women), 4,406 discontinued and 3,933 continued OAC. The risk of the primary outcome did not differ significantly between groups (weighted HR 0.93; 95% CI 0.67-1.29). Thromboembolic risk was similarly comparable (HR 0.96; 95% CI 0.69-1.35). Clinically relevant non-major bleeding occurred less frequently after OAC discontinuation (HR 0.68; 95% CI 0.47-0.97). Findings were consistent in sensitivity analyses. Annualized thromboembolic rates after discontinuation were <1% in patients with CHA2DS2-VA scores 2-3 but 1.52% in those with scores ≥4. CONCLUSIONS: Among patients without prior thromboembolism who remained arrhythmia-free at 6 months after AF ablation, OAC discontinuation was not associated with a difference in the composite outcome of stroke, systemic embolism and major bleeding, compared with OAC continuation. Residual risk remained low in patients with CHA2DS2-VA scores 2-3 but exceeded conventional thresholds in those with scores ≥4.
| Reference Key |
openalex_W7172407436
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Xiaodong Peng, Liu He, Jue Wang, Sitong Li, Qifan Li, Zixu Zhao, Zejun Yang, Mingxiao Li, Fadong Li, Xiaoxia Liu, Song Zuo, Xueyuan Guo, Junmeng Zhang, Ning Zhou, Yunlong Wang, Deyong Long, Caihua Sang, Xin Du, Jianzeng Dong, Changsheng Ma |
| Journal | EP Europace |
| Year | 2026 |
| DOI |
10.1093/europace/euag197
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.